CHEMOTHERAPY Nocardia asteroides tosufloxacin (T-3262) lied compound
Fig. 1. Susceptibility of Nocardia asteroides sensu stricto to tosufloxacin and other fluoroquinolones N. asteroides T-3262: tosufloxacin, CPFX : ciprofloxacin, OFLX : ofloxacin, ENX : enoxacin, NFLX : norfloxacin N. asteroides : Nocardia asteroides N. farcinica T-3262 : tosufloxacin, CPFX : ciprofloxacin, OFLX : ofloxacin, ENX : enoxacin, NFLX : norfioxacin N. farcinica : Nocardia farcinica Fig. 2. Susceptibility of Nocardia farcinica to tosufloxacin and other fluoroquinolones
CHEMOTHERAPY FEB. 1990 T-3262: tosufloxacin, CPFX: ciprofloxacin, OFLX: ofloxacin, ENX: enoxacin, NFLX: norfloxacin N. nova: Nocardia nova Fig. 3. Susceptibility of Nocardia nova to tosufloxacin and other fluoroquinolones N. farcinica: Nocardia farcinica, N. not a Nocardia nova Fig. 4. Binding of 14C-tosufloxacin to the cells of Nocardia farcinica (fluoroquinolone-sensitive species) and N nova (fluoroquinolone-resistant species)
VOL.38 NO.2 1) SIMPSOM G L, STINSON E B, EGGER M J, REMINGTON J S: Nocardia infections in the immunocompromised 2) host ; a detailed study in a defined population. Rev. Infect. Dis. 3: 492-507, 1981 BEAMAN B L, BURNSIDE J, EDWARD B, CAUSEY w: Nocardial infection in the United States, 1972-1974. J. Infect. Dis. 134 : 286-289, 1976 3) STEVENS D A, PIER A C, BEAMAN B L, MOROZUMI P A, LOVETT I S, HOUANG E T : Laboratory evaluation of an outbreak of nocardiosis in immunocompromised 934, 1981 host. Am. J. Med. 71: 928 4) SMEGO R A Jr, MOELLER M B, GALLIS H A. 5) Trimethoprim - sulfamethoxazole therapy for Nocardia infections. Arch. Intern. Med. 143: 711-718, 1983 COCKERILL III F R, EDSON R S, ROBERTS G D, WALDORF J C: Trimethoprim/sulfamethoxazole -resistant Nocardia asteroides causing multiple hepatic abscesses. Am. J. Med. 77 : 558-560, 6) 1984 MEIER B, METZGER U, MULLER F, SIEGENTHALER W, LUTHY R: Successful treatment of a pancreatic Nocardia asteroides abscess with amikacin and surgical drainage. Antimicrob. Agents Chemother. 29: 150-151, 1986 7) BACH M C, MONACO A P, FINLAND M : Pulmonary nocardiosis. Therapy with minocycline and with erythromycin plus ampicillin. J. M. A. M., 224 :1378-1381, 1973
CHEMOTHERAPY FEB. 1990 J. Antibiot.: in press. 11) YAZAWA K, MIKAMI Y, UNO J, ARM T: In vitro activity of flomoxef, a new axacephem group antibiotic against Nocardia. J. Antimicrob. Chemother., 1989, in press. 12) DANIEL T W, FERNANDES P B : Structure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 33: 131 `135, 1989 13) LEYSEN D C, HAEMERS A, PATTYN S R : Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. 33: 1 5, 1989 14) TSUKAMURA M, NAKAMURA E, YOSHII S, AMANO H: Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131: 352 356. 1985 16) GUTMANNL, GOLDSTEIN F W, KITZISMD, HAUTEFORT B, DARMON C, ACAR J F : Susceptibility of Nocardia asteroides to 46 antibiotics, including 22 Ĉ-lactams. Antimicrob. Agents Chemother. 23: 284 251, 1983 17) GOMBERT M E, AULICINO T M, Du BOUCHET L, BERKOWITZ L R: Susceptibility of Nocardia asteroides to new quinolones and Ĉ-lactams. Antimicrob. Agents Chemother. 31: 2013 2014, 1987 18) A UCKENTHALER R, MICHEA- HAMZEHPOUR M, PECHERE J C : In vitro activity of newer quinolones against aerobic bacteria. J. Antimicrob. Chemother. 17: Suppl. B, 29 39, 1986 19) TSUKAMURA M: Numerical taxonomy of the genus Nocardia. J. Gen. Microbiol. 45: 253 273, 1969 20) MIKAMI Y, YAZAWA K : Susceptibility patterns of pathogenic Nocardia to some selected antimicrobial agents and its taxonomic implication. Bullet. Japan Federation for Culture Collections. 5: 89 95, 1989 21) LECHEVALIER H A: Bergey's Manual of Systematic Bacteriology, Vol. 2. Nocardiforms (SNEATH P H A ed), pp.1458 1471, Williams & Wilkins 1986 22) TSUKAMURA M : Numerical analysis of the taxonomyof nocardiae and rhodococci. Division of Nocardia asteroides sensu stricto into two species and description of Nocardia paratuberculosis sp. nov. Tsukamura (formarly the Kyoto -1 group of Tsukamura), Nocardia nova sp. nov. Tsukamura, Rhodococcus ai. chiensis sp. nov. Tsukamura, Rhodococcus chubuensis sp. nov. Tsukamura, and Rhodo. coccus obuensis sp. nov. Tsukamura. Microbiol. Immunol. 26: 1101 ti 1119, 1982 23) SAT() K, INOUE Y, YAMASHITA S, INOUE M, M ITSUHASHI S: Inhibitory effects of ofloxacin and other new pyridone carboxylic acids on the activities of DNA gyrase isolated from Escherichia coli, Pseudomonas aerwginosa and Bacterioides twills., P.21 `25. Ofloxacin : A new quinolone antibacterial agent. In MITSUHASHI S, Dr^IKOS G K (ed) Proceedings of the 14th International Congress of Chemotherapy. University of Tokyo Press, 1986 24) HIRAI K, AOYAMA H, IICIKURA T, IYOSE S, MITSUHASHI S : Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coll. Antimicrob. Agents Chemother. 29: 535 538, 1986 25)ROBILLARD N J, SCARPA A L: Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aen ginosa PAD. Antimicrob. Agents Chemother. 32: 535 539, 1988 26)LEGAKIS N J, TZOUVELEKIS L S, MAKRIS A, KOTSIFAKI H: Outer membrane alteration in multiresistant mutants of Pseudomonas aen ginsosa selected by ciprofloxacin. Antimicrob. Agents Chemother. 33 : 124 127, 1989 27) COHEN S P, HooPER D C, WOLFSON J S, SOUZA K S, McM URRY L M, LEVY S B : Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob. Agents Chemother. 32: 1187-1191, 1988 28) HOOPER D C, WOLFSON J A, SOUZA K S, Ng E Y, McHUCH G L, SWARTZ M N : Mechanisms of quinolone resistance in Escherichia coli: Characterization of nfxb and cfxb, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob. Agents Chemother. 33: 283 290, 1989 `
VOL.38 NO,2 SPECIES SPECIFIC SUSCEPTIBILITY PATTERNS OF NOCARDIA ASTEROIDES GROUP TO TOSUFLOXACIN, A NEW FLUOROQUINOLONE AND BINDING PROFILES OF "C LABELLED COMPOUND TO SENSITIVE AND NON SENSITIVE NOCARDIA CELLS KATSUKIY0 YAZAWA, YUZURU MIKAMI and JUN UNO Department of Experimental Chemotherapy, Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, 1-8-1, Inohana Chiba 280, Japan AKIHIRO MATSUMAE Kitasato University The in vitro activity of tosufloxacin, a new fluoroquinolone, was compared with those of ciprofloxacin, ofloxacin, norfloxacin and enoxacin against the Nocardia asteroides group (N asteroides sensu stricto, Nocardia nova and Nocardia farcinica). Tosufloxacin was the most active fluoroquinolone and, in general, two to five times more active than other quinolones. Among the N asteroides group, N farcinica was highly sensitive and N nova was resistant to tosufloxacin. The mechanisms of these species - specific susceptibility patterns of the N asteroides group were further studied using "C-labelled tosufloxacin.